Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
								
																		
									
										
											Công thức hóa học
										
										
											
																						C21H26NO4																					
									 
																											
																		
									
																											
																		
									
										
											Monoisotopic mass 
										
										
											356.186183325										
									 
																											
									
																		
									
										
											InChI 
										
										
											InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22?/m1/s1										
									 
																		
																		
										
											InChI Key 
										
										
											InChIKey=JVLBPIPGETUEET-GAAHOAFPSA-O										
									 
																											
																		
										
											IUPAC Name 
										
										
											(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-4-methyl-14-oxo-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-trien-4-ium										
									 
																											
																		
										
											Traditional IUPAC Name 
										
										
											methylnaltrexone										
									 
																											
									
																		
										
											SMILES 
										
										
											[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CC[N+](C)(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O										
									 
																		
																		
									
																		
																		
																		
																											
																		
																											
																		
																											
																		
										
											pKa (strongest acidic) 
										
										
											7.4										
									 
																											
																		
										
											pKa (Strongest Basic) 
										
										
											-3.9										
									 
																											
																		
																											
																		
										
											Refractivity 
										
										
											107.42 m3·mol-1
										
									 
																			  
		  
																		
																											
																		
																		
									
																		
																		
																		
																		
																		
																		
																		
											  
		  
								 
							 	
														
															
								 Dược Lực Học : 
								
									Use of opioids induces slowing of gastrointestinal motility and transit. Following remifentanil administration, the methylnaltrexone and placebo groups showed no change in pupiliary constriction while the naloxone group showed a marked change over the time interval tested. 									
							
														
															
								 Cơ Chế Tác Dụng : 
								
									Methylnaltrexone is a pheriphally-acting μ-opioid antagonists that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008. 								
								
									Methylnaltrexone is a pheriphally-acting μ-opioid antagonists that acts on the gastrointestinal tract inhibit opioid-induced decrease in gastric motility and transit time. Because methylnaltrexone is a quaternary derivative of naltrexone, it produces its gastrointestinal effects without producing analgesic effects or withdrawal symptoms as it does not cross the blood-brain-barrier. 								
							
														
															
								 Dược Động Học  : 
								
									▧ Absorption : 
Methylnaltrexone is rapidly absorbed. 
Tmax (SubQ): 30 minutes (regardless of dose);
Cmax, 0.15 mg/kg SubQ dose = 117 ng/mL; 
AUC24, 0.15 mg/kg SubQ dose = 175 ng·hr/mL; 
▧ Volume of Distribution : 
Volume of distribution, steady state = 1.1 L/kg 
▧ Protein binding : 
11% to 15% bound to human plasma proteins. 
▧ Metabolism : 
60% of the dose is metabolized. Conversion to methyl-6-naltrexol isomers (5% of total dose) and methylnaltrexone sulfate (1.3% of total dose) appear to be the primary pathways of metabolism. N‑demethylation of methylnaltrexone to produce naltrexone is not significant. 
▧ Route of Elimination : 
Most of the drug is eliminated as unchanged drug (85% of administered radioactivity). Approximately half of the dose is excreted in the urine and somewhat less in feces.
▧ Half Life : 
terminal: 8.89 ± 2.59 h (intravenous) 
terminal: 6.14- 8.83 h (subcutaneous) 
▧ Clearance : 
10.5 ± 1.5 ml/min/kg (IV) 								
	
							 
														
														
								 Độc Tính : 
								
									LD50: 50 mg/kg (primates); 
Orthostatic hypotension at plasma levels in excess of 1.400 ng/mL. The most common (>5%) adverse reactions reported with methylnaltrexone bromide are abdominal pain, flatulence, nausea, dizziness, diarrhea and hyperhidrosis.									
							
														
							
																					
								 Chỉ Định : 
								
									Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy. 								
							
	
														
									
							
							
							
							
								
								 Liều Lượng & Cách Dùng : 
								
									Injection, solution - Subcutaneous - 12 mg/0.6 mL 
Injection, solution - Subcutaneous - 8 mg/0.4 mL 								
							
	
							
														
														
							
															
							
							
														
							
						
							
																													
								 Tài Liệu Tham Khảo Thêm 
								
																		
																		
																		
										
											National Drug Code Directory